March 11, 2015 - ZOLL LifeVest Wearable Defibrillator, Advanced Resuscitation Technology, and Temperature Management Solutions to Be Showcased at ACC 2015 CONTACT: Diane EganZOLL Medical Corporation+1 (978) email@example.com ZOLL LIFEVEST WEARABLE DEFIBRILLATOR, ADVANCED RESUSCITATION TECHNOLOGY, AND TEMPERATURE MANAGEMENT SOLUTIONS TO BE SHOWCASED AT ACC 2015 March 11, 2015—CHELMSFORD, MASS.—ZOLL® Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will display its portfolio of clinical resuscitation products, including the LifeVest® Wearable Defibrillator, along with sudden cardiac death (SCD) education and screening tools, in booth #1427 at the 2015 American College of Cardiology Annual Scientific Session and Expo, March 14-16 in San Diego. The LifeVest will be discussed during an Industry-Expert Theater event entitled “Effective Management of Newly Diagnosed Heart Failure Patients: Addressing SCD Risk During OMT Titration,” presented by Barry H. Greenberg, MD, University of California Medical Center, Saturday, March 14, 3:45-4:45 p.m., in Expo Hall #3545. Each year, more than 650,000 new cases of heart failure (HF) are diagnosed in the United States.1 Patients newly diagnosed with HF have a high mortality rate, up to 40% in the first year, including a high risk of sudden cardiac death (SCD).2 Compared to the general population, SCD occurs 6-9 times more frequently in HF patients,3 and an acute event such as hospitalization for heart failure decompensation or myocardial infarction increases the SCD risk.4,5 Likewise, an HF patient’s condition can improve from the benefits of optimized medical therapy, which can require up to 3 months or more to stabilize.6 The LifeVest protects patients at risk for SCD. It is used for a wide range of patient conditions or situations, including following a myocardial infarction, before or after coronary revascularization, and for those with cardiomyopathy or congestive heart failure that places them at particular risk. One in five post-acute myocardial infarction (AMI) patients have been shown to be at high risk of dying after percutaneous coronary intervention (PCI).7 The majority of mortality in AMI patients post-PCI occurs in the first three months—one out of every 10 high-risk patients die, with about 60% of this mortality due to SCD.7,8 The LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden death. The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart, and if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm. The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans. Additional products on display from ZOLL include: The R Series® Code-Ready® Defibrillators are designed to extend “Simple, Smart and Ready” defibrillation to every hospital department through advanced, cost-effective solutions for resuscitation. The original R Series ALS, and the R Series Plus, which has both AED and ALS capabilities at the touch of a button, offer See-Thru CPR®, a breakthrough technology that minimizes the duration of pauses in CPR to enable rescuers to see the underlying rhythm. Like all ZOLL defibrillators, the R Series also features Real CPR Help® audio and visual feedback for the correct depth and rate of chest compressions. ZOLL’s Intravascular Temperature Management (IVTM™) System offers health care providers the precision and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. The Thermogard XP® delivers accurate, easy-to-use and cost-effective control for both cooling and warming applications. This temperature management system provides a variety of catheter options depending upon the specific patient needs. The AutoPulse® Non-Invasive Cardiac Support Pump is an automated, portable chest compression device. The AutoPulse is the only mechanical CPR system to have shown improved outcomes in comparative clinical trials. In a meta-analysis of 12 comparative clinical trials, the AutoPulse improved the odds of return of spontaneous circulation (ROSC) by 62% compared to manual CPR.9 The CIRC trial, the largest prospective, randomized trial of mechanical chest compression ever completed, confirmed that the AutoPulse is equivalent to high-quality manual CPR for survival to hospital discharge.10 About ZOLL Medical Corporation ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com. About Asahi Kasei The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 29,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/. Copyright © 2015 ZOLL Medical Corporation. All rights reserved. AutoPulse, Code-Ready, IVTM, LifeVest, Real CPR Help, R Series, See-Thru CPR, Thermogard XP, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All product names are the property of their respective owners. 1 Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC. 2013;62(16):e147-e239. 2 O’Connor C, et al. Predictors of Mortality after Discharge in Patients Hospitalized with Heart Failure: An Analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Amer Heart J. 2008;156:662-73. 3 Rosamond W, et al., Heart Disease and Stroke Statistics32008 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117: e25-46. 4 Adabag AS, Therneau TM, Gersh BJ, et al. Sudden Death after Myocardial Infarction. JAMA. 2008;300:2022-2029. 5 Solomon SD, Zelenkofske S, McMurray JV, et al. Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. NEJM. 2005;352:2581-2588. 6 Hall SA, et al. Time Course of Improvement in Left Ventricular Function, Mass and Geometry in Patients with Congestive Heart Failure Treated with Beta-adrenergic Blockade. JACC. 1995;25:1154-61. 7 Halkin, A et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: CADILLAC Risk Score. JACC. 2005;45:1397–1405. 8 Stone, G et al. Prevention of Sudden Cardiac Arrest Post PTCA in High-Risk Patients. http://www.theheart.org/article/1202823.do (April 2011). 9 Wesfall M, et al. Mechanical Vs. Manual Chest Compressions in Out-of-Hospital Cardiac Arrest: A Meta-Analysis. Crit Care Med. 2013 Jul;41(7):1782‐9. 10 Wik L, et al. Manual vs. Integrated Automatic Load-distributing Band CPR with Equal Survival after Out- of- Hospital Cardiac Arrest. The Randomized CIRC Trial. Resuscitation 85 (2014) 741–748.